Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization?

Current Cardiology Reports
Ian J Sarembock, Dean J Kereiakes

Abstract

In acute coronary syndromes, risk stratification is essential, particularly in patients without ST elevation, and is based upon clinical, electrocardiogram (ECG), and biological markers. Among them, recent and repeated attacks of angina, ST-segment deviation from baseline on the admission ECG as well as elevated markers of myonecrosis (particularly increased troponin levels), myocardial dysfunction (B-type natriuretic peptide [BNP]; N-terminal prohormone of BNP[NT-proBNP]), and inflammation (high-sensitivity C-reactive protein) are predictors of an adverse outcome. These variables can be incorporated into broader risk predictive scores, among which the TIMI (Thrombolysis in Myocardial Infarction) and GRACE (Global Registry of Acute Coronary Events) scores are the most widely used. Two general therapeutic strategies (routine invasive vs conservative or selective invasive) are employed in the treatment of non-ST-segment elevation acute coronary syndrome (NSTEACS). Evidence-based analysis and the current American College of Cardiology/American Heart Association/Society for Cardiac Angiography and Interventions clinical practice guidelines recommend an early invasive treatment strategy (8-24 h) for intermediate or high clinical ris...Continue Reading

References

Jan 23, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Aug 1, 1989·Circulation·E Braunwald
Dec 1, 1993·Australian and New Zealand Journal of Medicine·P Aylward
May 23, 1998·The New England Journal of Medicine·UNKNOWN Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)
Feb 17, 2000·Journal of the American College of Cardiology·D A MorrowE Braunwald
Aug 11, 2000·JAMA : the Journal of the American Medical Association·E M AntmanE Braunwald
Jun 23, 2001·The New England Journal of Medicine·C P CannonUNKNOWN TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis
Oct 6, 2001·The New England Journal of Medicine·J A de LemosE Braunwald
Jul 5, 2002·The New England Journal of Medicine·Antonino BuffonAttilio Maseri
Oct 10, 2002·The American Journal of Cardiology·Benjamin M SciricaUNKNOWN Thrombolysis in Myocardial Ischemia III Registry Investigators
Dec 11, 2002·Journal of General Internal Medicine·David M KentHarry P Selker
Mar 26, 2003·Journal of the American College of Cardiology·Stefan K JamesUNKNOWN GUSTO-IV-ACS Investigators
Sep 4, 2003·Circulation·Stephan BaldusUNKNOWN CAPTURE Investigators
Oct 1, 2003·The American Journal of Cardiology·Brahmajee K Nallamothu, Eric R Bates
Oct 29, 2003·Archives of Internal Medicine·Christopher B GrangerUNKNOWN Global Registry of Acute Coronary Events Investigators
Nov 11, 2003·Journal of the American College of Cardiology·C Michael GibsonUNKNOWN TIMI Study Group
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv
Jun 16, 2005·JAMA : the Journal of the American Medical Association·Shamir R MehtaSalim Yusuf

❮ Previous
Next ❯

Citations

Jul 31, 2020·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Chloé Bernard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.